ArticleFrontiers in endocrinology2026
Feasibility of opportunistic bone health assessment using low-dose CT trabecular attenuation and
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: This study evaluated feasibility of this dual-parameter approach for opportunistic bone health assessment in prostate cancer. Design: This was a retrospective cross-sectional. Methods: A total of 105 men with prostate cancer without bone metastasis underwent Results: PET/CT-derived L1 trabecular attenuation agreed strongly with stand-alone diagnostic CT-L1, with a correlation coefficient of 0.929 and an intraclass correlation coefficient of 0.916. In the paired diagnostic CT, cross-validated discrimination for low diagnostic CT-L1 thresholds was already high with low-dose CT alone, and adding SUV did not improve performance. However, among 41 patients in the stand-alone diagnostic CT gray zone of 110-160 HU, 19 (46.3%) were classified as low Conclusions: In prostate cancer,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.